Log in

Relevant bibliographies by topics / Receptor NOP / Journal articles

To see the other types of publications on this topic, follow the link: Receptor NOP.

Journal articles on the topic 'Receptor NOP'

Author: Grafiati

Published: 4 June 2021

Last updated: 10 March 2023

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Receptor NOP.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Kiguchi, Norikazu, Huiping Ding, Shiroh Kishioka, and Mei-Chuan Ko. "Nociceptin/Orphanin FQ Peptide Receptor-Related Ligands as Novel Analgesics." Current Topics in Medicinal Chemistry 20, no. 31 (2020): 2878–88. http://dx.doi.org/10.2174/1568026620666200508082615.

Full text

Abstract:

Despite similar distribution patterns and intracellular events observed in the nociceptin/ orphanin FQ peptide (NOP) receptor and other opioid receptors, NOP receptor activation displays unique pharmacological profiles. Several researchers have identified a variety of peptide and nonpeptide ligands to determine the functional roles of NOP receptor activation and observed that NOP receptor- related ligands exhibit pain modality-dependent pain processing. Importantly, NOP receptor activation results in anti-nociception and anti-hypersensitivity at the spinal and supraspinal levels regardless of

APA, Harvard, Vancouver, ISO, and other styles

2

Zhuo, Guan-Yu, Ming-Chi Chen, Tzu-Yu Lin, Shih-Ting Lin, Daniel Tzu-Li Chen та Cynthia Wei-Sheng Lee. "Opioid-Modulated Receptor Localization and Erk1/2 Phosphorylation in Cells Coexpressing μ-Opioid and Nociceptin Receptors". International Journal of Molecular Sciences 24, № 2 (2023): 1048. http://dx.doi.org/10.3390/ijms24021048.

Full text

Abstract:

We attempted to examine the alterations elicited by opioids via coexpressed μ-opioid (MOP) and nociceptin/orphanin FQ (NOP) receptors for receptor localization and Erk1/2 (p44/42 MAPK) in human embryonic kidney (HEK) 293 cells. Through two-photon microscopy, the proximity of MOP and NOP receptors was verified by fluorescence resonance energy transfer (FRET), and morphine but not buprenorphine facilitated the process of MOP-NOP heterodimerization. Single-particle tracking (SPT) further revealed that morphine or buprenorphine hindered the movement of the MOP-NOP heterodimers. After exposure to m

APA, Harvard, Vancouver, ISO, and other styles

3

Bird, Mark F., Barbara Gallacher-Horley, John McDonald, et al. "In vitro sepsis induces Nociceptin/Orphanin FQ receptor (NOP) expression in primary human vascular endothelial but not smooth muscle cells." PLOS ONE 17, no. 9 (2022): e0274080. http://dx.doi.org/10.1371/journal.pone.0274080.

Full text

Abstract:

Sepsis is a dysregulated host response to infection that can cause widespread effects on other organs including cardiovascular depression, hypotension and organ failure. The receptor for Nociceptin/Orphanin FQ (N/OFQ), NOP is expressed on immune cells and these cells can release the peptide. Exogenous N/OFQ can dilate blood vessels and this peptide is increased in animal and human sepsis. We hypothesise that NOP receptors are present on vascular endothelial cells and therefore provide the target for released N/OFQ to cause vasodilation and hence hypotension. Using human umbilical vein endothel

APA, Harvard, Vancouver, ISO, and other styles

4

Bird, M. F., J. McDonald, B. Horley, et al. "MOP and NOP receptor interaction: Studies with a dual expression system and bivalent peptide ligands." PLOS ONE 17, no. 1 (2022): e0260880. http://dx.doi.org/10.1371/journal.pone.0260880.

Full text

Abstract:

Opioids targeting mu;μ (MOP) receptors produce analgesia in the peri-operative period and palliative care. They also produce side effects including respiratory depression, tolerance/dependence and addiction. The N/OFQ opioid receptor (NOP) also produces analgesia but is devoid of the major MOP side effects. Evidence exists for MOP-NOP interaction and mixed MOP-NOP ligands produce analgesia with reduced side effects. We have generated a HEKMOP/NOP human expression system and used bivalent MOP-NOP and fluorescent ligands to (i) probe for receptor interaction and (ii) consequences of that interac

APA, Harvard, Vancouver, ISO, and other styles

5

Mann, Anika, Lionel Moulédous, Carine Froment, et al. "Agonist-selective NOP receptor phosphorylation correlates in vitro and in vivo and reveals differential post-activation signaling by chemically diverse agonists." Science Signaling 12, no. 574 (2019): eaau8072. http://dx.doi.org/10.1126/scisignal.aau8072.

Full text

Abstract:

Agonists of the nociceptin/orphanin FQ opioid peptide (NOP) receptor, a member of the opioid receptor family, are under active investigation as novel analgesics, but their modes of signaling are less well characterized than those of other members of the opioid receptor family. Therefore, we investigated whether different NOP receptor ligands showed differential signaling or functional selectivity at the NOP receptor. Using newly developed phosphosite-specific antibodies to the NOP receptor, we found that agonist-induced NOP receptor phosphorylation occurred primarily at four carboxyl-terminal

APA, Harvard, Vancouver, ISO, and other styles

6

Zaveri, Nurulain T., Faming Jiang, Cris Olsen, Willma E. Polgar, and Lawrence Toll. "Designing bifunctional NOP receptor–mu opioid receptor ligands from NOP receptor-selective scaffolds. Part I." Bioorganic & Medicinal Chemistry Letters 23, no. 11 (2013): 3308–13. http://dx.doi.org/10.1016/j.bmcl.2013.03.101.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Blair Journigan, V., Willma E. Polgar, Taline V. Khroyan, and Nurulain T. Zaveri. "Designing bifunctional NOP receptor–mu opioid receptor ligands from NOP-receptor selective scaffolds. Part II." Bioorganic & Medicinal Chemistry 22, no. 8 (2014): 2508–16. http://dx.doi.org/10.1016/j.bmc.2014.02.047.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Holanda, Victor A. D., Salvatore Pacifico, Joaquim Azevedo Neto, et al. "Modulation of the NOP receptor signaling affects resilience to acute stress." Journal of Psychopharmacology 33, no. 12 (2019): 1540–49. http://dx.doi.org/10.1177/0269881119864942.

Full text

Abstract:

Background: The peptide nociceptin/orphanin FQ (N/OFQ) and its receptor (NOP) are implicated in the modulation of emotional states. Previous human and rodent findings support NOP antagonists as antidepressants. However, the role played by the N/OFQ–NOP receptor system in resilience to stress is unclear. Aims: The present study investigated the effects of activation or blockade of NOP receptor signaling before exposure to acute stress. Methods: The behavioral effects of the administration before stress of the NOP agonists Ro 65-6570 (0.01–1 mg/kg) and MCOPPB (0.1–10 mg/kg), and the NOP antagoni

APA, Harvard, Vancouver, ISO, and other styles

9

Whiteside, G. T., M. Hummel, T. Knappenberger, et al. "0001 Activation of Nociceptin/Orphanin-FQ Peptide (NOP) Receptors Produces an Increase in Non-REM Sleep in Rats and Constitutes a Novel and Attractive Target for the Treatment of Insomnia." Sleep 43, Supplement_1 (2020): A1. http://dx.doi.org/10.1093/sleep/zsaa056.000.

Full text

Abstract:

Abstract Introduction Treatments for insomnia have targeted GABA, histamine, serotonin, melatonin and orexin receptors. The nociceptin/orphanin-FQ peptide (NOP) receptor is widely expressed in the nervous system. High doses of NOP agonists administered systemically or locally into the CNS can result in sedation, however, the utility of targeting this receptor to treat insomnia has not been fully described. Methods V117957 is a recently described investigational oral, potent and selective NOP receptor partial agonist. We determined the brain Kp in whole brain and multiple sub-regions (50mg/kg)

APA, Harvard, Vancouver, ISO, and other styles

10

Margas, Wojciech, Khaled Sedeek та Victor Ruiz-Velasco. "Coupling Specificity of NOP Opioid Receptors to Pertussis-Toxin-Sensitive Gα Proteins in Adult Rat Stellate Ganglion Neurons Using Small Interference RNA". Journal of Neurophysiology 100, № 3 (2008): 1420–32. http://dx.doi.org/10.1152/jn.90405.2008.

Full text

Abstract:

The opioid receptor-like 1 (NOP or ORL1) receptor is a G-protein-coupled receptor the endogenous ligand of which is the heptadecapeptide, nociceptin (Noc). NOP receptors are known to modulate pain processing at spinal, supraspinal, and peripheral levels. Previous work has demonstrated that NOP receptors inhibit N-type Ca2+ channel currents in rat sympathetic stellate ganglion (SG) neurons via pertussis toxin (PTX)-sensitive Gαi/o subunits. However, the identification of the specific Gα subunit that mediates the Ca2+ current modulation is unknown. The purpose of the present study was to examine

APA, Harvard, Vancouver, ISO, and other styles

11

Ubaldi, Massimo, Nazzareno Cannella, Anna Maria Borruto, et al. "Role of Nociceptin/Orphanin FQ-NOP Receptor System in the Regulation of Stress-Related Disorders." International Journal of Molecular Sciences 22, no. 23 (2021): 12956. http://dx.doi.org/10.3390/ijms222312956.

Full text

Abstract:

Nociceptin/orphanin FQ (N/OFQ) is a 17-residue neuropeptide that binds the nociceptin opioid-like receptor (NOP). N/OFQ exhibits nucleotidic and aminoacidics sequence homology with the precursors of other opioid neuropeptides but it does not activate either MOP, KOP or DOP receptors. Furthermore, opioid neuropeptides do not activate the NOP receptor. Generally, activation of N/OFQ system exerts anti-opioids effects, for instance toward opioid-induced reward and analgesia. The NOP receptor is widely expressed throughout the brain, whereas N/OFQ localization is confined to brain nuclei that are

APA, Harvard, Vancouver, ISO, and other styles

12

Schröder, W., D. G. Lambert, M. C. Ko, and T. Koch. "Functional plasticity of the N/OFQ-NOP receptor system determines analgesic properties of NOP receptor agonists." British Journal of Pharmacology 171, no. 16 (2014): 3777–800. http://dx.doi.org/10.1111/bph.12744.

Full text

APA, Harvard, Vancouver, ISO, and other styles

13

Zhang, Lan, Ulrike M. Stamer, Melody Ying-Yu Huang, and Frank Stüber. "Interactions between the Nociceptin and Toll-like Receptor Systems." Cells 11, no. 7 (2022): 1085. http://dx.doi.org/10.3390/cells11071085.

Full text

Abstract:

Nociceptin and the nociceptin receptor (NOP) have been described as targets for treatment of pain and inflammation, whereas toll-like receptors (TLRs) play key roles in inflammation and impact opioid receptors and endogenous opioids expression. In this study, interactions between the nociceptin and TLR systems were investigated. Human THP-1 cells were cultured with or without phorbol myristate acetate (PMA 5 ng/mL), agonists specific for TLR2 (lipoteichoic acid, LTA 10 µg/mL), TLR4 (lipopolysaccharide, LPS 100 ng/mL), TLR7 (imiquimod, IMQ 10 µg/mL), TLR9 (oligonucleotide (ODN) 2216 1 µM), PMA+

APA, Harvard, Vancouver, ISO, and other styles

14

Bird, M. F., C. P. Hebbes, S. W. M. Scott, J. Willets, J. P. Thompson, and D. G. Lambert. "A novel bioassay to detect Nociceptin/Orphanin FQ release from single human polymorphonuclear cells." PLOS ONE 17, no. 5 (2022): e0268868. http://dx.doi.org/10.1371/journal.pone.0268868.

Full text

Abstract:

Nociceptin/Orphanin FQ (N/OFQ) is the endogenous opioid agonist for the N/OFQ receptor or NOP. This receptor system is involved in pain processing but also has a role in immune regulation. Indeed, polymorphonuclear cells (PMNs) express mRNA for N/OFQ precursor and are a potential source for circulating N/OFQ. Current measurements are based on ELISA and RIA techniques. In this study we have designed a bioassay to measure N/OFQ release from single PMNs. Chinese Hamster Ovary (CHO) cells transfected with the human (h) NOP receptor and Gαiq5 chimera force receptor coupling in biosensor cells to in

APA, Harvard, Vancouver, ISO, and other styles

15

Pacifico, Salvatore, Valentina Albanese, Davide Illuminati, et al. "Novel Mixed NOP/Opioid Receptor Peptide Agonists." Journal of Medicinal Chemistry 64, no. 10 (2021): 6656–69. http://dx.doi.org/10.1021/acs.jmedchem.0c02062.

Full text

APA, Harvard, Vancouver, ISO, and other styles

16

Zhang, Yanan, David Perrey, and Jun-Xu Li. "Modified Synthesis of NOP Receptor Antagonist SB612111." Synthesis 49, no. 06 (2016): 1394–400. http://dx.doi.org/10.1055/s-0036-1588379.

Full text

APA, Harvard, Vancouver, ISO, and other styles

17

El Daibani, Amal, and Tao Che. "Spotlight on Nociceptin/Orphanin FQ Receptor in the Treatment of Pain." Molecules 27, no. 3 (2022): 595. http://dx.doi.org/10.3390/molecules27030595.

Full text

Abstract:

In our society today, pain has become a main source of strain on most individuals. It is crucial to develop novel treatments against pain while focusing on decreasing their adverse effects. Throughout the extent of development for new pain therapies, the nociceptin/orphanin FQ receptor (NOP receptor) has appeared to be an encouraging focal point. Concentrating on NOP receptor to treat chronic pain with limited range of unwanted effects serves as a suitable alternative to prototypical opioid morphine that could potentially lead to life-threatening effects caused by respiratory depression in ove

APA, Harvard, Vancouver, ISO, and other styles

18

Camilleri, Michael. "Toward an effective peripheral visceral analgesic: responding to the national opioid crisis." American Journal of Physiology-Gastrointestinal and Liver Physiology 314, no. 6 (2018): G637—G646. http://dx.doi.org/10.1152/ajpgi.00013.2018.

Full text

Abstract:

This mini-review summarizes recent new developments in visceral analgesics. This promising field is important, as a new approach to address abdominal pain with peripheral visceral analgesics is considered a key approach to addressing the current opioid crisis. Some of the novel compounds address peripheral pain mechanisms through modulation of opioid receptors via biased ligands, nociceptin/orphanin FQ opioid peptide (NOP) receptor, or dual action on NOP and μ-opioid receptor, buprenorphine and morphiceptin analogs. Other compounds target nonopioid mechanisms, including cannabinoid (CB2), N-me

APA, Harvard, Vancouver, ISO, and other styles

19

Faouzi, Abdelfattah, Balazs R. Varga, and Susruta Majumdar. "Biased Opioid Ligands." Molecules 25, no. 18 (2020): 4257. http://dx.doi.org/10.3390/molecules25184257.

Full text

Abstract:

Achieving effective pain management is one of the major challenges associated with modern day medicine. Opioids, such as morphine, have been the reference treatment for moderate to severe acute pain not excluding chronic pain modalities. Opioids act through the opioid receptors, the family of G-protein coupled receptors (GPCRs) that mediate pain relief through both the central and peripheral nervous systems. Four types of opioid receptors have been described, including the μ-opioid receptor (MOR), κ-opioid receptor (KOR), δ-opioid receptor (DOR), and the nociceptin opioid peptide receptor (NOP

APA, Harvard, Vancouver, ISO, and other styles

20

Ding, Huiping, Paul W. Czoty, Norikazu Kiguchi, et al. "A novel orvinol analog, BU08028, as a safe opioid analgesic without abuse liability in primates." Proceedings of the National Academy of Sciences 113, no. 37 (2016): E5511—E5518. http://dx.doi.org/10.1073/pnas.1605295113.

Full text

Abstract:

Despite the critical need, no previous research has substantiated safe opioid analgesics without abuse liability in primates. Recent advances in medicinal chemistry have led to the development of ligands with mixed mu opioid peptide (MOP)/nociceptin-orphanin FQ peptide (NOP) receptor agonist activity to achieve this objective. BU08028 is a novel orvinol analog that displays a similar binding profile to buprenorphine with improved affinity and efficacy at NOP receptors. The aim of this preclinical study was to establish the functional profile of BU08028 in monkeys using clinically used MOP rece

APA, Harvard, Vancouver, ISO, and other styles

21

Dumitrascuta, Maria, Marcel Bermudez, Olga Trovato, et al. "Antinociceptive Efficacy of the µ-Opioid/Nociceptin Peptide-Based Hybrid KGNOP1 in Inflammatory Pain without Rewarding Effects in Mice: An Experimental Assessment and Molecular Docking." Molecules 26, no. 11 (2021): 3267. http://dx.doi.org/10.3390/molecules26113267.

Full text

Abstract:

Opioids are the most effective analgesics, with most clinically available opioids being agonists to the µ-opioid receptor (MOR). The MOR is also responsible for their unwanted effects, including reward and opioid misuse leading to the current public health crisis. The imperative need for safer, non-addictive pain therapies drives the search for novel leads and new treatment strategies. In this study, the recently discovered MOR/nociceptin (NOP) receptor peptide hybrid KGNOP1 (H-Dmt-D-Arg-Aba-β-Ala-Arg-Tyr-Tyr-Arg-Ile-Lys-NH2) was evaluated following subcutaneous administration in mouse models

APA, Harvard, Vancouver, ISO, and other styles

22

Leo, MA, MD, Raphael J. "Potential innovative targets in the treatment of pain: Combined μ and NOP receptor agonists". Journal of Opioid Management 17, № 4 (2021): 277–83. http://dx.doi.org/10.5055/jom.2021.0659.

Full text

Abstract:

Opioid analgesics are potent and widely used medications employed to manage moderate-to-severe acute pain; their utility in the management of chronic inflammatory and neuropathic pain is modest and is beset with adverse effects and concerns related to abuse and addiction. The discovery of the nonclassical opioid, ie, the nociception/orphanin receptor (NOP), has sparked interest into another possible analgesic target. Preclinical studies have demonstrated pain mitigating effects associated with NOP receptor activation while simultaneously reducing conventional μ-opioid-related adverse and eupho

APA, Harvard, Vancouver, ISO, and other styles

23

Gavioli, Elaine C., and Pedro R. T. Romão. "NOP Receptor Ligands as Potential Agents for Inflammatory and Autoimmune Diseases." Journal of Amino Acids 2011 (November 17, 2011): 1–10. http://dx.doi.org/10.4061/2011/836569.

Full text

Abstract:

Nociceptin/orphanin FQ (N/OFQ) is a seventeen-amino acid peptide that is the endogenous ligand of a G-protein-coupled receptor (NOP). Various immune cells express the precursor protein and secrete N/OFQ as well as display binding sites for this peptide. The functional capacity of NOP receptor was demonstrated in vitro and in vivo studies by the ability of N/OFQ to induce chemotaxis of immune cells, to regulate the expression of cytokines and other inflammatory mediators, and to control cellular and humoral immunity. In this context, N/OFQ could modulate the outcome of some inflammatory disease

APA, Harvard, Vancouver, ISO, and other styles

24

Raffa, R. B., G. Burdge, J. Gambrah, et al. "Cebranopadol: novel dual opioid/NOP receptor agonist analgesic." Journal of Clinical Pharmacy and Therapeutics 42, no. 1 (2016): 8–17. http://dx.doi.org/10.1111/jcpt.12461.

Full text

APA, Harvard, Vancouver, ISO, and other styles

25

Mustazza, Carlo, and Giuditta Bastanzio. "Development of nociceptin receptor (NOP) agonists and antagonists." Medicinal Research Reviews 31, no. 4 (2010): 605–48. http://dx.doi.org/10.1002/med.20197.

Full text

APA, Harvard, Vancouver, ISO, and other styles

26

Ertin, Ismet Hande, Ozgur Gunduz, and Ahmet Ulugol. "Contribution of nociceptin/orphanin FQ receptors to the anti-nociceptive and hypothermic effects of dipyrone." Acta Neuropsychiatrica 27, no. 1 (2014): 48–52. http://dx.doi.org/10.1017/neu.2014.38.

Full text

Abstract:

BackgroundDipyrone is one of the most commonly used non-opioid analgesic and antipyretic drug. Its anti-nociceptive and hypothermic effects have long been suspected to be centrally mediated. The involvement of the most recently discovered opioid peptide, nociceptin/orphanin FQ (N/OFQ), and its receptor (NOP) in pain transmission is controversial. It appears to be pro-nociceptive when administered supra-spinally, but exerts anti-nociceptive effects when injected spinally or systemically.ObjectiveInvestigation of the role of the N/OFQ system in paracetamol-induced anti-nociception and hypothermi

APA, Harvard, Vancouver, ISO, and other styles

27

Puls, Kristina, Helmut Schmidhammer, Gerhard Wolber та Mariana Spetea. "Mechanistic Characterization of the Pharmacological Profile of HS-731, a Peripherally Acting Opioid Analgesic, at the µ-, δ-, κ-Opioid and Nociceptin Receptors". Molecules 27, № 3 (2022): 919. http://dx.doi.org/10.3390/molecules27030919.

Full text

Abstract:

Accumulated preclinical and clinical data show that peripheral restricted opioids provide pain relief with reduced side effects. The peripherally acting opioid analgesic HS-731 is a potent dual μ-/δ-opioid receptor (MOR/DOR) full agonist, and a weak, partial agonist at the κ-opioid receptor (KOR). However, its binding mode at the opioid receptors remains elusive. Here, we present a comprehensive in silico evaluation of HS-731 binding at all opioid receptors. We provide insights into dynamic interaction patterns explaining the different binding and activity of HS-731 on the opioid receptors. Fo

APA, Harvard, Vancouver, ISO, and other styles

28

James, Arul, and John Williams. "Basic Opioid Pharmacology — An Update." British Journal of Pain 14, no. 2 (2020): 115–21. http://dx.doi.org/10.1177/2049463720911986.

Full text

Abstract:

Opioids are a group of analgesic agents commonly used in clinical practice. The three classical opioid receptors are MOP, DOP and KOP. The NOP (N/OFQ) receptor is considered to be a non-opioid branch of the opioid receptor family. Opioid receptors are G-protein-coupled receptors which cause cellular hyperpolarisation when bound to opioid agonists. Opioids may be classified according to their mode of synthesis into alkaloids, semi-synthetic and synthetic compounds. Opioid use disorder (OUD) is an emerging issue and important lessons can be learnt from the United States where opioid epidemic was

APA, Harvard, Vancouver, ISO, and other styles

29

Ozawa, Akihiko, Gloria Brunori, Daniela Mercatelli, et al. "Knock-In Mice with NOP-eGFP Receptors Identify Receptor Cellular and Regional Localization." Journal of Neuroscience 35, no. 33 (2015): 11682–93. http://dx.doi.org/10.1523/jneurosci.5122-14.2015.

Full text

APA, Harvard, Vancouver, ISO, and other styles

30

Toll, Lawrence, Akihiko Ozawa, and Andrea Cippitelli. "Involvement of NOP receptors, the fourth opioid receptor, on pain and drug abuse." IBRO Reports 6 (September 2019): S13. http://dx.doi.org/10.1016/j.ibror.2019.07.027.

Full text

APA, Harvard, Vancouver, ISO, and other styles

31

Spagnolo, B., G. Calo, W. E. Polgar та ін. "Activities of mixed NOP and μ-opioid receptor ligands". British Journal of Pharmacology 153, № 3 (2008): 609–19. http://dx.doi.org/10.1038/sj.bjp.0707598.

Full text

APA, Harvard, Vancouver, ISO, and other styles

32

Malfacini, Davide, Katharina Simon, Claudio Trapella, et al. "NOP receptor pharmacological profile – A dynamic mass redistribution study." PLOS ONE 13, no. 8 (2018): e0203021. http://dx.doi.org/10.1371/journal.pone.0203021.

Full text

APA, Harvard, Vancouver, ISO, and other styles

33

Khroyan, Taline V., Willma E. Polgar, Juan Orduna, et al. "Activity of new NOP receptor ligands in a rat peripheral mononeuropathy model: Potentiation of morphine anti-allodynic activity by NOP receptor antagonists." European Journal of Pharmacology 610, no. 1-3 (2009): 49–54. http://dx.doi.org/10.1016/j.ejphar.2009.03.019.

Full text

APA, Harvard, Vancouver, ISO, and other styles

34

Wainford, Richard D., and Daniel R. Kapusta. "Chronic high-NaCl intake prolongs the cardiorenal responses to central N/OFQ and produces regional changes in the endogenous brain NOP receptor system." American Journal of Physiology-Regulatory, Integrative and Comparative Physiology 296, no. 2 (2009): R280—R288. http://dx.doi.org/10.1152/ajpregu.00096.2008.

Full text

Abstract:

Intracerebroventricular nociceptin/orphanin FQ (N/OFQ) produces cardiovascular depressor, diuretic, and renal sympathoinhibitory responses in conscious rats. These studies examined how a chronic high-NaCl intake alters these peptide-evoked responses and the activity of the endogenous central N/OFQ peptide (NOP) receptor system. In normotensive Sprague-Dawley rats fed a chronic (3-wk) high (8%)-NaCl diet, intracerebroventricular N/OFQ (5.5 nmol) produced prolonged bradycardic, hypotensive, and diuretic responses but failed to suppress renal sympathetic nerve activity. In a separate group of rat

APA, Harvard, Vancouver, ISO, and other styles

35

Mustazza, Carlo, Stefano Pieretti, and Francesca Marzoli. "Nociceptin /Orphanin FQ Peptide (NOP) Receptor Modulators: An Update in Structure-Activity Relationships." Current Medicinal Chemistry 25, no. 20 (2018): 2353–84. http://dx.doi.org/10.2174/0929867325666180111095458.

Full text

Abstract:

Nociceptin /Orphanin FQ Peptide” receptor (NOPr) is a G-protein-coupled receptor with the nociceptin/orphanin FQ peptide (N/OFQ) as endogenous agonist. It is expressed in the nervous system as well as in some non-neural tissues. Its activation has pronociceptive effect at the supraspinal level, whereas at the spinal level it produces nociceptive effects at low doses and antinociceptive effects at higher doses. NOPr is also involved in mood and blood pressure regulation, immunoregulation, airway constriction, feeding, urination, bowel motility, learning and memory. Selective NOPr agonists have

APA, Harvard, Vancouver, ISO, and other styles

36

Koizumi, Miwako, Kazuto Sakoori, Naoko Midorikawa, and Niall P. Murphy. "The NOP (ORL1) receptor antagonist Compound B stimulates mesolimbic dopamine release and is rewarding in mice by a non-NOP-receptor-mediated mechanism." British Journal of Pharmacology 143, no. 1 (2004): 53–62. http://dx.doi.org/10.1038/sj.bjp.0705906.

Full text

APA, Harvard, Vancouver, ISO, and other styles

37

Hossain, Mohammad Zakir, Hiroshi Ando, Shumpei Unno, and Junichi Kitagawa. "Targeting Peripherally Restricted Cannabinoid Receptor 1, Cannabinoid Receptor 2, and Endocannabinoid-Degrading Enzymes for the Treatment of Neuropathic Pain Including Neuropathic Orofacial Pain." International Journal of Molecular Sciences 21, no. 4 (2020): 1423. http://dx.doi.org/10.3390/ijms21041423.

Full text

Abstract:

Neuropathic pain conditions including neuropathic orofacial pain (NOP) are difficult to treat. Contemporary therapeutic agents for neuropathic pain are often ineffective in relieving pain and are associated with various adverse effects. Finding new options for treating neuropathic pain is a major priority in pain-related research. Cannabinoid-based therapeutic strategies have emerged as promising new options. Cannabinoids mainly act on cannabinoid 1 (CB1) and 2 (CB2) receptors, and the former is widely distributed in the brain. The therapeutic significance of cannabinoids is masked by their ad

APA, Harvard, Vancouver, ISO, and other styles

38

Gear, R. W., O. Bogen, L. F. Ferrari, P. G. Green, and J. D. Levine. "NOP receptor mediates anti-analgesia induced by agonist–antagonist opioids." Neuroscience 257 (January 2014): 139–48. http://dx.doi.org/10.1016/j.neuroscience.2013.10.061.

Full text

APA, Harvard, Vancouver, ISO, and other styles

39

Adem, Abdu, Nather Madjid, Ulrika Kahl, et al. "Nociceptin and the NOP receptor in aversive learning in mice." European Neuropsychopharmacology 27, no. 12 (2017): 1298–307. http://dx.doi.org/10.1016/j.euroneuro.2017.09.005.

Full text

APA, Harvard, Vancouver, ISO, and other styles

40

Mustazza, Carlo, and Giuditta Bastanzio. "ChemInform Abstract: Development of Nociceptin Receptor (NOP) Agonists and Antagonists." ChemInform 42, no. 47 (2011): no. http://dx.doi.org/10.1002/chin.201147238.

Full text

APA, Harvard, Vancouver, ISO, and other styles

41

Sullo, Nikol, Fiorentina Roviezzo, Maria Matteis, et al. "Nociceptin/orphanin FQ receptor activation decreases the airway hyperresponsiveness induced by allergen in sensitized mice." American Journal of Physiology-Lung Cellular and Molecular Physiology 304, no. 10 (2013): L657—L664. http://dx.doi.org/10.1152/ajplung.00358.2012.

Full text

Abstract:

Several studies suggest that the N/OFQ (nociceptin/orphanin FQ)-NOP (N/OFQ peptide) receptor pathway is involved in airway physiology. We previously demonstrated a modulation of the endogenous N/OFQ levels in allergen-sensitized mice. Here, we investigated the effects of NOP receptor activation in allergen sensitization using a murine model of allergen-induced airway hyperresponsiveness (AHR). BALB/c mice were intraperitoneally treated with the NOP receptor agonist UFP-112, either during the sensitization phase (30 min before ovalbumin administration) or at the end of sensitization process (15

APA, Harvard, Vancouver, ISO, and other styles

42

Zaveri, Nurulain, Faming Jiang, Cris Olsen, Willma Polgar, and Lawrence Toll. "Small-molecule agonists and antagonists of the opioid receptor-like receptor (ORL1, NOP): Ligand-based analysis of structural factors influencing intrinsic activity at NOP." AAPS Journal 7, no. 2 (2005): E345—E352. http://dx.doi.org/10.1208/aapsj070234.

Full text

APA, Harvard, Vancouver, ISO, and other styles

43

Wright, Danyeal M., Keri M. Small, Subodh Nag, and Sukhbir S. Mokha. "Activation of Membrane Estrogen Receptors Attenuates NOP-Mediated Tactile Antihypersensitivity in a Rodent Model of Neuropathic Pain." Brain Sciences 9, no. 6 (2019): 147. http://dx.doi.org/10.3390/brainsci9060147.

Full text

Abstract:

Women manifest a higher prevalence of several chronic pain disorders compared to men. We demonstrated earlier that estrogen rapidly attenuates nociceptin/orphanin FQ (N/OFQ) peptide receptor (NOP)-mediated thermal antinociception through the activation of membrane estrogen receptors (mERs). However, the effect of mER activation on NOP-mediated attenuation of tactile hypersensitivity in a neuropathic model of pain and the underlying mechanisms remain unknown. Following spared nerve injury (SNI), male and ovariectomized (OVX) female rats were intrathecally (i.t.) injected with a selective mER ag

APA, Harvard, Vancouver, ISO, and other styles

44

Giakomidi, Despina, Mark F. Bird, John McDonald та ін. "Evaluation of [Cys(ATTO 488)8]Dermorphin-NH2 as a novel tool for the study of μ-opioid peptide receptors". PLOS ONE 16, № 4 (2021): e0250011. http://dx.doi.org/10.1371/journal.pone.0250011.

Full text

Abstract:

The μ-opioid peptide (MOP) receptor is a member of the opioid receptor family and an important clinical target for analgesia. Measuring MOP receptor location and tracking its turnover traditionally used radiolabels or antibodies with attendant problems of utility of radiolabels in whole cells and poor antibody selectivity. To address these issues we have synthesized and characterised a novel ATTO488 based fluorescent Dermorphin analogue; [Cys(ATTO 488)8]Dermorphin-NH2 (DermATTO488). We initially assessed the binding profile of DermATTO488 in HEK cells expressing human MOP and CHO cells express

APA, Harvard, Vancouver, ISO, and other styles

45

Zhou, Wei, Aman Mahajan, and John C. Longhurst. "Spinal nociceptin mediates electroacupuncture-related modulation of visceral sympathoexcitatory reflex responses in rats." American Journal of Physiology-Heart and Circulatory Physiology 297, no. 2 (2009): H859—H865. http://dx.doi.org/10.1152/ajpheart.00149.2009.

Full text

Abstract:

The role of nociceptin and its spinal cord neural pathways in electroacupuncture (EA)-related inhibition of visceral excitatory reflexes is not clear. Nociceptin/orphanin FQ (N/OFQ) is an endogenous ligand for a G protein-coupled receptor, called the N/OFQ peptide (NOP) receptor, which has been found to be distributed in the spinal cord. The present study investigated the importance of this system in visceral-cardiovascular reflex modulation during EA. Cardiovascular pressor reflex responses were induced by gastric distension in Sprague-Dawley rats anesthetized by ketamine and xylazine. An int

APA, Harvard, Vancouver, ISO, and other styles

46

Petrocelli, Giovannamaria, Luca Pampanella, Provvidenza M. Abruzzo, Carlo Ventura, Silvia Canaider, and Federica Facchin. "Endogenous Opioids and Their Role in Stem Cell Biology and Tissue Rescue." International Journal of Molecular Sciences 23, no. 7 (2022): 3819. http://dx.doi.org/10.3390/ijms23073819.

Full text

Abstract:

Opioids are considered the oldest drugs known by humans and have been used for sedation and pain relief for several centuries. Nowadays, endogenous opioid peptides are divided into four families: enkephalins, dynorphins, endorphins, and nociceptin/orphanin FQ. They exert their action through the opioid receptors (ORs), transmembrane proteins belonging to the super-family of G-protein-coupled receptors, and are expressed throughout the body; the receptors are the δ opioid receptor (DOR), μ opioid receptor (MOR), κ opioid receptor (KOR), and nociceptin/orphanin FQ receptor (NOP). Endogenous opio

APA, Harvard, Vancouver, ISO, and other styles

47

Olszewski, Pawel K., and Allen S. Levine. "Minireview: Characterization of Influence of Central Nociceptin/Orphanin FQ on Consummatory Behavior." Endocrinology 145, no. 6 (2004): 2627–32. http://dx.doi.org/10.1210/en.2004-0016.

Full text

Abstract:

Abstract Nociceptin/orphanin FQ (N/OFQ), a peptide closely related to dynorphin A, is the endogenous agonist of the NOP receptor that moderately increases food intake under various conditions. Its orexigenic properties are mediated by the brain circuitry. In the present review, we focus on discussing the nature of hyperphagic effects of N/OFQ with special emphasis on its function within feeding-related neural networks. Although some of N/OFQ’s orexigenic effects resemble those induced by opioids, reward-dependent feeding appears to be affected in a different manner by agonists of the NOP and c

APA, Harvard, Vancouver, ISO, and other styles

48

Rawls, Scott M., Joseph A. Schroeder, Zhe Ding, Tony Rodriguez, and Nurulain Zaveri. "NOP receptor antagonist, JTC-801, blocks cannabinoid-evoked hypothermia in rats." Neuropeptides 41, no. 4 (2007): 239–47. http://dx.doi.org/10.1016/j.npep.2007.03.001.

Full text

APA, Harvard, Vancouver, ISO, and other styles

49

Targowska-Duda, Katarzyna M., Akihiko Ozawa, Zachariah Bertels, et al. "NOP receptor agonist attenuates nitroglycerin-induced migraine-like symptoms in mice." Neuropharmacology 170 (June 2020): 108029. http://dx.doi.org/10.1016/j.neuropharm.2020.108029.

Full text

APA, Harvard, Vancouver, ISO, and other styles

50

Trombella, S., R. Vergura, S. Falzarano, R. Guerrini, G. Calo, and S. Spisani. "Nociceptin/orphanin FQ stimulates human monocyte chemotaxis via NOP receptor activation." Peptides 26, no. 8 (2005): 1497–502. http://dx.doi.org/10.1016/j.peptides.2005.03.015.

Full text

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!